Skip to content
MarketScale
‹ Back to IndustriesSciences

Intermittent Fasting Can Benefit People with Type 2 Diabetes. Can “Mindful Eating” Provide Similar Health Rewards with Less Structure?

To improve holistic bodily health, intermittent fasting may replace snack time for many, possibly even for people with type 2 diabetes. A recent review out of the journal Clinical Diabetes and Endocrinology shows evidence that intermittent fasting can reduce not only body weight but insulin resistance as well in people with type 2 diabetes, along with…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · FastingIntermittent FastingMindful EatingRamadan
Share

Key takeaways

01

To improve holistic bodily health, intermittent fasting may replace snack time for many, possibly even for people with type 2 diabetes.

02

A recent review out of the journal Clinical Diabetes and Endocrinology shows evidence that intermittent fasting can reduce not only body weight but insulin resistance as well in people with type 2 diabetes, along with…

To improve holistic bodily health, intermittent fasting may replace snack time for many, possibly even for people with type 2 diabetes. A recent review out of the journal Clinical Diabetes and Endocrinology shows evidence that intermittent fasting can reduce not only body weight but insulin resistance as well in people with type 2 diabetes, along with helping regulate levels of the hormone leptin, which signals the brain when a person is full. As worldwide diabetes projections rise to 643 million by 2030 and 783 million by 2045, and 1.4 million Americans are diagnosed with diabetes yearly, the science and healthcare communities are weighing a wide variety of options for how to treat this epidemic. What role does intermittent fasting play in those options, and are there similar strategies that would act as a better alternative?

The most common method to produce intermediate fasting benefits is time-restricted feeding. It allows for eating during specific hours a day, with 16–20-hour daily fasts. This isn’t the only fasting strategy, though, and the concept of intermittent fasting in fact has a rich history. Another approach is daily fasting from dawn to sunset as practiced during Ramadan. A recent study in Metabolism Open focuses on this type of intermittent fasting which aligns meal and sleep times with the body’s natural rhythm. It may have potential benefits such as optimizing the body’s immune functions.

Common across these versions of fasting is a structured, repeated and consistent pace to eating (or not eating). A less structured approach, though, such as mindful eating, may be just as beneficial. Sheila H. Forman, licensed clinical psychologist, mindful eating coach and founder of TAME Your Appetite, gives a healthy serving of advice on the benefits of intermittent fasting, and why a mindful eating strategy could prove just as useful for scientists and physicians to tackle related health crises. 

Sheila’s Thoughts

“Intermittent fasting is the intentional withholding of food and drink for hours at a time without regard to the body’s hunger and fullness. Proponents of intermittent fasting say that intentionally fasting may have health benefits. For example, giving the body this period of rest gives it a chance to use its own energy and stores things like sugar and fat before more food is consumed.

In addition, intermittent fasting is also said to provide health benefits because it purposefully reduces the amount of food, namely calories that a person consumes any given day. We all know that a reduction in calories has been shown to help with diseases. A reduction in calories has been shown to reduce the risk of things like obesity, heart disease, cancer, dementia, and diabetes.

In our 24/7 world, it is easy to eat excessively and never truly give our bodies a chance to rest or properly digest the food that it has previously eaten. But you don’t have to use intermittent fasting to accomplish all these health benefits.

Mindful eating can do that for you while also honoring your body’s own hunger and fullness signals, also known as using inner wisdom. Mindful eating very simply is eating with the awareness of your body’s needs and preferences. When a person pays attention to their body and allows their body to guide them what, when, and how much to eat, they naturally have periods of time in their day when they’re not eating and their body is actively and efficiently processing and utilizing the food previously eaten, and those episodes will be in sync with their body’s actual needs, and not created by the specific timeframes that are imposed by intermittent fasting.

Furthermore, with practice, the mindful eater learns how to eat the right amount of calories for their body so that any excess weight that they may be carrying is lost. So if a person is looking for a way to enhance their health by making sure that their body is given the time it needs to do its thing, they have to look no further than their own inner wisdom and a mindful approach to eating.”

Article written by Sonya Young.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512